Rituximab

Idiopathic Pulmonary Fibrosis

Clinical trials

Developer

National Institute of Allergy and Infectious Diseases (NIAID)

Overview

Rituximab is an agent tracked by PF-Atlas in the context of idiopathic pulmonary fibrosis. It appears in 11 tracked IPF clinical trials.

Rituximab clinical trials

NCT01086540 (Phase 2)NCT01862926 (Phase 2)NCT02990286 (Phase 3)NCT05596786 (Phase 3)NCT03069248 (Phase 2)NCT01969409 (Phase 2)NCT01748084 (Phase 2)NCT06549231 (Phase 3)NCT04783675 (Phase 2)NCT00578565 (Phase 3)NCT04531865 (Phase 3)

Explore related

All trials Research

Medical disclaimer. This page summarizes research about Rituximab for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.